Wells Fargo Initiates Coverage On Beta Bionics with Overweight Rating, Announces Price Target of $28

Benzinga Newsdesk www.benzinga.com Neutral 71.8%

Neg 0% Neu 71.8% Pos 0%

Wells Fargo analyst Larry Biegelsen initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Overweight rating and announces Price Target of $28.